NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Dr Liau's talk on Oct 27 may give some answers?
Dr. Liau’s lecture “Targeting Treatment-induced Resistance in Glioblastoma”

antihama

Re: flipper44 post# 523964

Sunday, October 23, 2022 1:16:30 PM

Post#
524150
of 524168
Dr Liau's talk on Oct 27 may give some answers?
Dr. Liau’s lecture “Targeting Treatment-induced Resistance in Glioblastoma”

https://events.med.upenn.edu/xrt/event/771352-radiation-oncology-invited-speaker-seminar-series
flipper44

Member Level
Re: None

Saturday, October 22, 2022 7:06:25 AM

Post#
523964
of 524166
Was reading through this article, and realized I had forgotten a basic tenant regarding TMZ, not only causes myelosuppression, it also causes t-cell exhaustion. https://jeccr.biomedcentral.com/articles/10.1186/s13046-022-02251-2

Just thinking through the NYAS results with that in mind, it is important to remember DCVax-l dendritic cells’ primary functional role is to educate/actuate effector t-cells which then go kill the tumor cells.

If TMZ doses are too high, and we already know standard dosing is too high for this consideration, concurrent TMZ would be reducing a facet of DCVax-l care, even though TMZ helps at another level by blocking DNA repair of tumor cells.

With that in mind, recall that rGBM in the DCVax-l trial was not treated with TMZ, only DCVax-l. Of course the treatment with TMZ occurred before rGBM when it was nGBM, but all that came to a screeching halt after progression.

You may think I’m going to come to some grand conclusion about what the remaining data might demonstrate, however, instead, I’m simply waiting (like everyone else) to see how this all fits together upon release of more information.

Just keep in mind, when you see more data on the trial, that TMZ can cause t-cell exhaustion at standard and higher doses. Keep in mind that the trial tracked TMZ usage, and keep in mind in mind that recurrent GBM patients (control and treatment arm crossovers) no longer received TMZ.